BioSpace News Archive

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the fourth quarter and full year ended December 31, 2019.

BioTelemetry, Inc., the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, reported results for the quarter and year ended December 31, 2019.

Arena Pharmaceuticals, Inc. provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2019.

EMIT Corporation announced that it has been awarded a five-year $20 million maximum contract, effective February 20, 2020, from the Defense Logistics Agency Troop Support, Philadelphia, PA for purchase of its HypothermX® Intravenous Fluid and Blood Warming Devices and related accessories on their electronic catalogue.

Jazz Pharmaceuticals plc announced that the company will webcast its corporate presentations at the following investor conferences

REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, announced financial results for the fourth quarter and full year ended December 31, 2019, and recent operational highlights.

Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced that David Fischel, Chairman and CEO, will present at three investor conferences in March 2020.

NanoString Technologies, Inc., a leading provider of life science tools for translational research, reported financial results for the fourth quarter and year ended December 31, 2019.

Active Motif Shanghai, in collaboration with Fudan University and its affiliated Public Health Clinical Center, used its single-cell AbEpic™ screening technology to isolate antibodies from patients recovering from 2019 Coronavirus related pneumonia.

The board of directors of Cigna Corporation declared a cash dividend of $0.04 per share of Cigna common stock, payable on April 9, 2020 to shareholders of record as of the close of business on March 10, 2020.